Patent ruling in Europe puts Inspire Medical Systems under legal spotlight Inspire Medical Systems (INSP) now faces a fresh legal overhang in Europe after the Unified Patent Court in Munich issued a default decision in favor of rival Nyxoah over a contested European patent. For investors tracking Inspire Medical Systems, the latest legal setback in Europe comes on top of a weak run in the share price. The 30 day share price return is down 13.64% and the year to date share price return is down...
Check out the companies making headlines this week:
Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.
Inspire Medical Systems Inc (INSP) posted $206.7 million in Q3 revenue amid a $120 million reimbursement headwind, while securing a Category 1 CPT code and projecting a return to growth in 2027.
Inspire Medical Systems remains fundamentally strong despite severe reimbursement and coding disruptions. Click here to read this INSP stock update.
Inspire Medical Systems has been treated as a profitable, high‑margin sleep apnea growth story, yet Q3 2026 told a harsher tale. The company posted revenue of US$206.7m with a clear squeeze in earnings, as basic EPS flipped to a loss of US$0.84 and net income fell to a loss of US$24.4m. That reality hit investor sentiment hard. The stock dropped about 7.9% today to US$61.90, extending recent weakness and signaling that the market is rapidly rethinking how much pressure on profitability it is...
MINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026. Inspire is scheduled to present at 2:40 p.m. Eastern Time. The presentation will be accessible via a live we
Inspire Medical Systems (NYSE:INSP) reported third-quarter revenue of $206.7 million, down 7.9% from a year earlier but up 3% sequentially, as stronger-than-expected U.S. performance offset weaker international results. The company said coding and reimbursement challenges continued to weigh on resul
Third quarter revenue of $206.7 millionThird quarter diluted EPS of $(0.84); adjusted diluted EPS of $0.14Third quarter operating cash flow of $46.4 millionAMA CPT® Editorial Panel approved new Category I CPT codes for single lead hypoglossal nerve stimulation, including Inspire V, set to take effect January 1, 2028 MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and comme
Detailed price information for Monolithic Power Sys (MPWR-Q) from The Globe and Mail including charting and trades.
Inspire Medical Systems gains 47.8% in three months as improved reimbursement clarity, an earnings beat, $30 million in annual savings and new CPT codes boost recovery prospects.
Detailed price information for Inspire Medical Systems Inc (INSP-N) from The Globe and Mail including charting and trades.
MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2026 after the close of trading on Monday, November 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Ins
In October 2026, Inspire Medical Systems announced that the AMA CPT Editorial Panel approved new Category I CPT codes that specifically cover the Inspire V system, with these codes scheduled to take effect on January 1, 2028 and to guide future Medicare payment determinations. This coding milestone highlights growing clinical acceptance of Inspire’s closed-loop implantable therapy for obstructive sleep apnea and sets the stage for more standardized reimbursement processes across...
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Inspire Medical Systems (NYSE:INSP) and its peers.
Inspire Medical Systems (NYSE:INSP) demonstrates strong core gross economics with a 85.5% gross margin, $415.2 million in cash and investments, and a raised 2026 revenue guidance range of $835 million to $875 million. The company centers on its expanded patient reach, with over 140,000 patients treated, and its high-margin Inspire V system driving operational cash […]
Inspire Medical Systems has seen its share price fall sharply over several years, and that slide raises a pointed question about whether the current market value still lines up with the cash the business is expected to generate. With the stock now well below past peaks, the key issue is how today’s US$69.36 price compares with its future cash flow profile. The share price decline of 71.2% over 5 years puts long term expectations for Inspire Medical Systems’ cash generation under the...
Shares of medical technology company Inspire Medical Systems (NYSE:INSP) jumped 7.4% in the morning session after Stifel analyst Jonathan Block raised the price target on the company to $80.00 from $75.00 while maintaining a Buy rating.
This is the newest page. Registered accounts read further back.